Search This Blog

Thursday, July 4, 2019

5 Plant-Based Meat Makers That Could Give Beyond Meat A Run For Its Money

Beyond Meat Inc BYND 1.23%‘s stellar run since its Wall Street debut on May 2 has turned the spotlight on plant-based meat companies.
Plant-based meat products are substitutes that mimic the properties of actual meat, and therefore look and taste like meat. The telling proof for the popularity of these products is Beyond Meat’s recently released results, which revealed a 215% jump in first-quarter net sales.
The lucrative market opportunity is likely to allure more and more players.
The following are companies that are bracing to make a name for themselves in the up-and-coming market for plant-based meat products.

Tyson Foods

Tyson Foods, Inc. TSN 1.08% announced in mid-June that it has introduced the first plant-based and blended products under the brand name “Raised & Rooted,” marking its foray into the alternative protein segment.
The company announced plans to roll out its initial products — plant-based nuggets as well as blended burgers and a beef-plant combo product — at several of its major retail customers.

Nestle

Swiss food giant Nestle NSRGY 0.02% revealed on April 2 plans to launch 100% plant-based burgers in Europe and the U.S., with the U.S. launch planned for fall.
The company said the burgers don’t compromise on flavor, texture and cooking experience.
“We believe this trend is here to stay, as consumers look at different ways to enjoy and balance their protein intake and lower the environmental footprint of their diets,” the company said in the release.

ConAgra

Conagra Brands Inc CAG 5.96%, which recently reported disappointing quarterly results, is eyeing an opportunity in the space through the Gardein brand, which came into its stable through its 2018 Pinnacle Foods acquisition. The brand has a presence in food service and a strong market positioning in plant-based meat alternatives at the retail level.
The company quantified the market opportunity for plant-based meat alternatives at $30 billion in the U.S. alone.

Impossible Foods

Based in Redwood, California and founded in 2011, privately held Impossible Foods develops plant-based substitutes for meat and dairy products. It launched its flagship product, the Impossible Burger, in 2016, and also makes plant-based sausage products.

Hormel Foods

Hormel Foods Corp HRL 1.33% recently said at the Deutsche Bank dbAccess Global Conference that it has been working on meat substitutes in multiple channels over the past several years.
The company has introduced the Fuse burger, which is a blend of meat and some plant-based items. One of its food service subsidiaries is working on a plant-based pizza topping.

FDA Places Unum’s Early Stage Cancer Drug Trial On Clinical Hold

Unum Therapeutics Inc UMRX 3.2% shares were under pressure Wednesday following a clinical trial update provided by the company late Tuesday.

What Happened

The FDA has imposed a clinical hold on the Phase 1 ATTCK-20-2 trial that evaluated ACTR087 in combination with Roche Holdings AG Basel ADR RHHBY 0.25%‘s rituximab following lymphodepleting chemotherapy with fludarabine and cyclophosphamide in patients with relapsed/refractory CD20+ B cell non-Hodgkin lymphoma.
A clinical hold is an order issued by the FDA to delay an ongoing clinical trial or altogether suspend it; enrolled patients may not be given the investigational drug and new patient enrollment is halted.
The FDA action comes after Unum submitted a safety report regarding one patient in cohort 3 of the trial who experienced serious adverse events that included Grade 3 neurotoxicity, cytomegalovirus infection and Grade 4 respiratory distress.

Why It’s Important

Unum, which provides curative T-cell therapies to treat a broad range of cancer patients, went public in May 2018.
Since closing at $12.90, a 24% premium over its IPO price of $12, the stock has lost much of its value.
In its S-1 filing ahead of the IPO, Unum disclosed two deaths in its ACTR087 trial, with one resulting from enterococcal sepsis related to the investigational drug and another from unrelated sepsis.
The company said it has deprioritized its onetime lead product candidate ACTR087 and is now focusing on its new ACTR construct ACTR707 in combination with rituximab for the same indication.

What’s Next

Unum said the FDA has agreed that patients who previously received ACTR087 and have clinical responses may continue to receive rituximab infusions, with continued monitoring for adverse events.
The company said it will work closely with the FDA to further review these events and report data from the ATTCK-20-2 trial at the end of 2019.

Kellogg Rallies As Columnist Reviews MorningStar Farms Grillers Veg Burger

Kellogg K 6.27% shares rallied after a MarketWatch columnist shared why he thinks, “Kellogg is sitting on a ‘fake meat’ gold mine bigger than Beyond Meat,” adding that MorningStar Grillers’ vegetarian burgers are better than Beyond Meat’s BYND 1.23% Beyond Burgers.
MarketWatch columnist Brett Arends points out that Morningstar Farms is a division of Kellogg and produces vegetarian food. This means Kellogg owns the largest single “fake meat” operation.
MorningStar’s “Grillers” vegetarian burgers, according to Arends, are “way better than Beyond Meat’s, Beyond Burgers.”
The MorningStar Grillers are mainly made of soy. Arends makes the point that anyone watching the stock market, reading the news or watching the news knows there’s a sudden Wall Street mania for so-called “fake meat” burgers. Beyond Meat shares skyrocketed sixfold since its IPO two months ago.

Blood pressure drug linked with increased risk of diverticulosis

This condition causes small bulges or pouches to appear in the lining of the intestine. Particularly affecting the elderly (as many as 65 per cent of over 85s may be affected), diverticulosis can in some cases can lead to a medical emergency if the pouches become infected or burst.
The new early-stage research finding comes from a team of scientists led by Imperial College London, who investigated the effectiveness and side effects of three common blood pressure medications: ACE-inhibitors, beta-blockers and .
High blood pressure affects one in ten adults across the globe, and increases the risk of heart attack and stroke. The most common treatments for high blood pressure are  and medications.
However, despite the three main medications being taken by millions, investigating their potential side effects (as well as studying their effectiveness for treating other diseases), can be difficult and often involves lengthy and expensive clinical trials.
To overcome this problem, the research team, led by Imperial’s School of Public Health, used  to study the effects of the drugs.
By investigating versions of genes that mimic the effects of these drugs, the team were able to study the drugs’ effectiveness—and their potential .
First, the researchers, who published their work in the journal Circulation, identified the proteins targeted by the drugs, and which help lower blood pressure. Next, they analysed genetic data from around 750,000 people and identified the so-called genetic variants that code for these proteins.
The team, who included researchers from LMU Munich, then studied whether these gene variants—which cause increased production of these proteins—were linked to an increased or decreased risk of other diseases.
The good news was that, as expected, these so-called genetic variants (which coded for proteins involved in lowering blood pressure) were linked to lower heart disease and stroke risk.
However after assessing the risk of around 900 different diseases—using data from the UK Biobank study—the team found that the versions of genes related to the effects of a particular type of calcium channel blocker—the non-dihydropyridine class, were linked to an increased the risk of a bowel condition called diverticulosis.
The team compared their findings with further , and supported the potential link with an increased risk of the bowel condition.
The link now needs further investigation with larger trials, explains Dr. Dipender Gill, co-lead author of the research from Imperial’s School of Public Health: “This is the first time that this class of blood pressure drug has been associated with diverticulosis. We’re not sure of the underlying mechanism—although it may relate to effects on the function of intestine muscles, which perform contractions to transport food through the gut.”
Dr. Joanna Tzoulaki, senior author from Imperial’s School of Public Health added: “The study of genetic variants that mimic the effect of drugs is evolving as a powerful concept to help prioritise clinical trials and design clinical trials more likely to be successful”.
Dr. Gill cautions the findings should not change current prescribing guidelines and that people should not stop taking their medication unless first consulting their doctor.
He added: “These findings should not change clinical practice, but instead should act as a catalyst for further research.”

Explore further

Journal information: Circulation

Vermont places 92 percent tax on E-cigarettes

A  92 percent tax on electronic cigarettes took effect in Vermont on Monday as the state tries to reduce young people’s use of the devices.
That rate means that e-cigarettes will now cost about the same as combustible cigarettes, CBS News reported.
The e-cigarette tax increase bill was sponsored by State Rep. George Till, who said it will help keep the products out of the hands of young people. “We know the group that is most sensitive to price is teenager,” he told CBS News. “And we know that these companies are going out of their way to get kids addicted.”
Two other measures meant to reduce youth smoking also took effect in Vermont on Monday. One raised the legal age for buying and using cigarettes, e-cigarettes, and tobacco products to 21 from 18, and the other restricts retail and online sales of tobacco and related products, CBS News reported. Just last week, San Francisco became the first U.S. city to ban the sale, distribution, and manufacturing of  products.

Explore further

More information: CBS News Article

FDA accepts Insys’ NDA for naloxone nasal spray for opioid overdose

The FDA has accepted Insys Therapeutics’ (NASDAQ:INSY) NDA for its investigational, naloxone nasal spray for the emergency treatment of opioid overdose in both adult and pediatric patients.
A single unit dose spray device delivers 8mg naloxone dose.

Morphosys up on €22M milestone from Glaxo

Morphosys AG (NASDAQ:MOR) is up 4% premarket on light volume on the heels of the launch of licensee GlaxoSmithKline’s late-stage program for rheumatoid arthritis med otilimab.
The dosing of the first patient will trigger a €22M milestone payment from GSK. As a result, MOR is boosting its 2019 guidance for revenue to €65M – 72 from €43M – 50M and EBIT loss of (€105M – 115M) from (€127M – 137M). All other guidance remains as is.